KRAS amplification in colorectal cancer: correlations with clinicopathological features and prognosis in patients and prediction of response to targeted therapy
KRAS amplification constitutes a distinct oncogenic driver in CRC and a potential biomarker for therapeutic stratification. Our findings support the clinical rationale for dual MEK and CDK4/6 inhibition in KRAS-amplified CRC and highlight the need for biomarker-guided clinical trials to optimize treatment strategies in this subset of patients.
Authors
- Ping Lan (ORCID: https://orcid.org/0000-0002-8901-8498)
- Shuitu Feng (ORCID: https://orcid.org/0000-0002-6343-8654)
- Xuanhua Yang (ORCID: https://orcid.org/0009-0005-6644-627X)
- Qi Zhang (ORCID: https://orcid.org/0000-0002-1905-0468)
- Wenxin Li (ORCID: https://orcid.org/0000-0001-6660-477X)
- Shujuan Li (ORCID: https://orcid.org/0000-0003-4740-9615)
- Min Zhi
- Sijing Cheng (ORCID: https://orcid.org/0000-0003-0837-0826)
Institutions
- Sun Yat-sen University (CN)
- Sixth Affiliated Hospital of Sun Yat-sen University (CN)
- Third Affiliated Hospital of Zhengzhou University (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-07-24
- DOI
- https://doi.org/10.1186/s12967-025-06864-x
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Basic and Applied Basic Research Foundation of Guangdong Province